Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $70.00.

Tonix Pharmaceuticals Stock Up 6.0%

TNXP stock opened at $16.55 on Friday. Tonix Pharmaceuticals has a twelve month low of $6.76 and a twelve month high of $69.97. The company has a market cap of $201.41 million, a P/E ratio of -0.83 and a beta of 1.78. The business has a fifty day moving average of $17.28 and a 200-day moving average of $27.93.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, November 10th. The company reported ($3.59) EPS for the quarter, hitting analysts’ consensus estimates of ($3.59). The firm had revenue of $3.29 million during the quarter, compared to analyst estimates of $2.30 million. Tonix Pharmaceuticals had a negative return on equity of 55.19% and a negative net margin of 963.39%. As a group, equities research analysts anticipate that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in shares of Tonix Pharmaceuticals during the second quarter worth $25,000. Ameritas Investment Partners Inc. bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at $28,000. Russell Investments Group Ltd. acquired a new stake in Tonix Pharmaceuticals during the 3rd quarter worth $29,000. Police & Firemen s Retirement System of New Jersey bought a new position in Tonix Pharmaceuticals during the second quarter worth about $62,000. Finally, BNP Paribas Financial Markets acquired a new position in Tonix Pharmaceuticals in the second quarter valued at about $65,000. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.